265. 脂肪萎縮症 Disease details / Clinical trials / Drug dev / DR info

13 valent conjugated pneumococcal vaccine
   Medical University of South Carolina
      2015   Early Phase 1   NCT03039491   United States
150 MG GSK1265744B
   ViiV Healthcare
      2013   Phase 1   NCT01848340   United States
300MG gemcabene
   Elif Oral
      2018   Phase 1/Phase 2   NCT03508687   United States
3TC
   Kirby Institute
      2004   Phase 4   NCT00192621   Australia
60-minutes OF steady state exercise
   University of Exeter
      2019   -   NCT04056000   United Kingdom
600MG gemcabene
   Elif Oral
      2018   Phase 1/Phase 2   NCT03508687   United States
Abacavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
Abacavir 300MG twice daily
   Gilead Sciences
      2003   Phase 2   NCT00647946   United Kingdom
Abacavir sulfate
   Glaxo Wellcome
      2000   Phase 4   NCT00005764   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2002   -   NCT00028314   United States
Abacavir sulfate, lamivudine and zidovudine
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 2   NCT00021463   United States
Acetate
   Theratechnologies Inc.
      2007   Phase 3   EUCTR2007-003233-16-GB   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-FR   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-ES   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-BE   Belgium;France;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-005444-88-GB   Belgium;France;Germany;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-005444-88-FR   Belgium;France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005444-88-ES   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005444-88-DE   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005444-88-BE   Belgium;France;Germany;Spain;United Kingdom
Acetyl- L- carnitine
   SIGMA-TAU
      2006   -   EUCTR2005-004665-42-IT   Italy
Acetylcarnitine
   SIGMA-TAU
      2006   -   EUCTR2005-004665-42-IT   Italy
Acipimox
   National Heart, Lung, and Blood Institute (NHLBI)
      2002   -   NCT00246402   United States
Akcea-angptl3-LRX
   Akcea Therapeutics
      2018   Phase 2   NCT03514420   United States
Amplification BY PCR and direct sequencing ON THE entire coding sequence and intron-exons boundaries OF THE candidate gene
   University Hospital, Bordeaux
      2014   -   NCT02056912   France
Amprenavir
   Glaxo Wellcome
      1998   -   NCT00002417   United States
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
Antiretroviral/anti HIV
   Augusta University
      2020   Phase 4   NCT04340388   United States
Aramchol
   University of California, San Diego
      2016   Phase 2   NCT02684591   United States
Atazanavir
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-002740-10-IT   Germany;Italy;Spain;United Kingdom
   Bristol-Myers Squibb
      2005   Phase 4   NCT00135356   Canada;France;Germany;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom
   Clinical Alliance for Research & Education - Infectious Diseases, LLC.
      2006   Phase 4   NCT00426296   United States
Atazanavir/ritonavir
   National Institute of Allergy and Infectious Diseases (NIAID)
      2002   -   NCT00028314   United States
Atorvastatin calcium
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00017758   United States
ATV
   Bristol-Myers Squibb
      2005   Phase 4   NCT00135356   Canada;France;Germany;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom
Avandia administration FOR 6-12 weeks
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1999   Phase 1   NCT00006185   United States
AZT
   Kirby Institute
      2004   Phase 4   NCT00192621   Australia
AZT/3TC
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom
Baricitinib
   Eli Lilly and Company
      2020   Phase 2/Phase 3   NCT04517253   Japan
      2012   -   NCT01724580   United Kingdom;United States
      -   Phase 2;Phase 3   EUCTR2025-000001-16-Outside-EU/EEA   Japan
Berberine
   Hospital Civil de Guadalajara
      2021   Phase 3   NCT04860063   -
BMS-232632
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom
Bood and urine sampling
   Centre Hospitalier Universitaire de la Réunion
      2023   -   NCT06107439   Réunion
Caffeine
   University of Exeter
      2019   -   NCT04056000   United Kingdom
Carnitine
   Queen's University
      2002   Phase 4   NCT00202228   Canada
CD-4 guided therapy interruption
   Hospital Clinic of Barcelona
      2002   Phase 4   NCT00646984   Spain
Cholic acid
   University of Texas Southwestern Medical Center
      2006   Phase 2   NCT00457639   United States
Combivir
   Kirby Institute
      2004   Phase 4   NCT00192621   Australia
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom
Cyclophosphamide
   Children's Hospital of Fudan University
      2019   -   NCT03936829   China
Diagnostic test
   Theratechnologies
      2022   -   NCT05383456   United States
Didanosine
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
Different haart regimens
   Danish HIV Research Group
      2004   Phase 4   NCT00139178   Denmark
Diosmin
   ALIO MEDICA Sp. z o.o.
      2014   -   EUCTR2013-004539-57-PL   Poland
Diosminex, 500 MG, tabletki powlekane
   ALIO MEDICA Sp. z o.o.
      2014   -   EUCTR2013-004539-57-PL   Poland
Dolutegravir
   Thomas Benfield
      2021   Phase 4   NCT04903847   Denmark
Dolutegravir / lamivudine oral tablet
   Thomas Benfield
      2020   Phase 4   NCT04904406   Denmark
Dolutegravir 50 MG
   Augusta University
      2020   Phase 4   NCT04340388   United States
Doravirine
   Thomas Benfield
      2021   Phase 4   NCT04903847   Denmark
Efavirenz
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 2   NCT00021463   United States
      2001   Phase 1   NCT00017758   United States
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 4   NCT00006190   United States
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom
   University of Texas Southwestern Medical Center
      2002   Phase 4   NCT00457665   United States
Emtricitabine/tenofovir
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom
Enfuvirtide
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
Exercise
   Baylor College of Medicine
      2004   -   NCT00246376   United States
Exercise training
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2005   -   NCT00656851   United States
      2005   -   NCT00639457   United States
Fenofibrate
   Baylor College of Medicine
      2004   -   NCT00246376   United States
   National Institute of Allergy and Infectious Diseases (NIAID)
      2000   Phase 3   NCT00006412   Puerto Rico;United States
Glycerine GEL
   Venus Concept
      2015   -   NCT02492997   United States
Growth hormone
   Hvidovre University Hospital
      2005   Phase 4   NCT00119769   Denmark
   Theratechnologies Inc.
      2007   Phase 3   EUCTR2007-003233-16-GB   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-FR   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-ES   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-BE   Belgium;France;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-005444-88-GB   Belgium;France;Germany;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-005444-88-FR   Belgium;France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005444-88-ES   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005444-88-DE   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005444-88-BE   Belgium;France;Germany;Spain;United Kingdom
Growth hormone releasing hormone
   Massachusetts General Hospital
      2009   -   NCT00795210   United States
GSK1265744B (sodium salt) containing 14C-GSK1265744B
   ViiV Healthcare
      2013   Phase 1   NCT01848340   United States
HIGH-carbohdyrate breakfast
   University of Exeter
      2019   -   NCT04056000   United Kingdom
HIGH-dose REGN4461
   Regeneron Pharmaceuticals
      2020   Phase 2   NCT04159415   Peru;Russian Federation;Turkey;United States
HIV ANTI-retroviral background therapy
   Theratechnologies
      2022   -   NCT05383456   United States
Indinavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
Isis 304801
   Akcea Therapeutics
      2016   Phase 2;Phase 3   EUCTR2015-000493-35-PT   Belgium;Brazil;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Akcea Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-000493-35-DE   Belgium;Brazil;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   IONIS PHARMACEUTICALS, INC.
      2015   Phase 2;Phase 3   EUCTR2015-000493-35-IT   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-000493-35-GR   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000493-35-BE   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Isis Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2015-000493-35-NL   Australia;Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2015-000493-35-ES   Australia;Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2015   Phase 2   NCT02639286   United States
Lamivudine
   Kirby Institute
      2004   Phase 4   NCT00192621   Australia
      2003   Phase 4   NCT00192660   Australia
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 4   NCT00006190   United States
   Thomas Benfield
      2021   Phase 4   NCT04903847   Denmark
Lamivudine/zidovudine
   Glaxo Wellcome
      2000   Phase 4   NCT00005764   United States
Leptin
   Baylor College of Medicine
      2003   -   NCT01511016   United States
   Beth Israel Deaconess Medical Center
      2006   Phase 2   NCT00362440   United States
   Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine Translational Research Center, Kyoto University Hospital
      2010   -   JPRN-UMIN000002818   Japan
   Kyoto University Hospital
      2010   -   JPRN-UMIN000003679   Japan
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 2   NCT00005905   United States
   University of Texas Southwestern Medical Center
      2006   Phase 2/Phase 3   NCT00896298   United States
      2003   Phase 2   NCT00461552   United States
Lopinavir
   Kirby Institute
      2004   Phase 4   NCT00192621   Australia
Lopinavir/ritonavir
   National Institute of Allergy and Infectious Diseases (NIAID)
      2002   -   NCT00028314   United States
Lopinavir/ritonavir + nevirapine
   VU University Medical Center
      2003   Phase 4   NCT00122226   Finland;Netherlands;Spain;United Kingdom
Lopinavir/ritonavir + zidovudine + lamivudine
   VU University Medical Center
      2003   Phase 4   NCT00122226   Finland;Netherlands;Spain;United Kingdom
LOW-dose REGN4461
   Regeneron Pharmaceuticals
      2020   Phase 2   NCT04159415   Peru;Russian Federation;Turkey;United States
LY3009104
   Eli Lilly and Company
      -   Phase 2;Phase 3   EUCTR2025-000001-16-Outside-EU/EEA   Japan
Mecasermin
   University of Texas Southwestern Medical Center
      2011   Phase 1   NCT01329744   United States
Mediterranean diet
   Federico II University
      2023   -   NCT06236932   Italy
Melatonin supplementation
   Federico II University
      2023   -   NCT06236932   Italy
Metformin
   Tufts Medical Center
      2011   Phase 4   NCT01612858   United States
Metformin hydrochloride
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   -   NCT00015691   United States
Metreleptin
   Aegerion Pharmaceuticals, Inc.
      2018   Phase 4   NCT04026178   United States
      2016   -   NCT02325674   France;Germany;Italy;United Kingdom;United States
   Amryt Pharma
      2025   Phase 3   NCT06502990   Belgium;France;Germany;Italy
      2024   Phase 3   NCT06679270   United States
      2024   Phase 4   NCT06484868   France;Germany;Italy;United Kingdom
      2021   Phase 3   NCT05164341   Belgium;Brazil;Canada;Chile;Israel;Netherlands;Poland;Spain;United States
   Baylor College of Medicine
      2003   -   NCT01511016   United States
   Bristol-Myers Squibb
      2008   -   NCT00677313   United States
   Medical University of Vienna
      2018   Phase 2   EUCTR2017-003014-22-AT   Austria
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2014   Phase 3   NCT02262832   United States
      2014   Phase 2   NCT02262806   United States
      2013   Phase 2   NCT01778556   United States
      2001   Phase 2   NCT00025883   United States
   University of Michigan
      2015   Phase 2   NCT02654977   United States
      2012   Phase 2   NCT01679197   United States
      2011   -   NCT02404896   United States
Metrelpetin
   Medical University of Vienna
      2018   Phase 2   EUCTR2017-003014-22-AT   Austria
Mibavademab
   Regeneron Pharmaceuticals
      2024   Phase 3   NCT06548100   United States
Monotherapy (lopinavir/ritonavir) + ABC/3TC
   Fundacion SEIMC-GESIDA
      2008   Phase 4   NCT00865007   Spain
Myalept
   Medical University of Vienna
      2018   Phase 2   EUCTR2017-003014-22-AT   Austria
Nelfinavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
   University of Texas Southwestern Medical Center
      2002   Phase 4   NCT00457665   United States
Nelfinavir mesylate
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00017758   United States
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 4   NCT00006190   United States
Nevirapine
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
   National Institute of Allergy and Infectious Diseases (NIAID)
      2002   -   NCT00028314   United States
      2001   Phase 2   NCT00021463   United States
Niacin
   Baylor College of Medicine
      2004   -   NCT00246376   United States
NON-nucleoside reverse transcriptase inhibitors
   French National Agency for Research on AIDS and Viral Hepatitis
      2003   Phase 4   NCT00122668   France
      2001   Phase 4   NCT00122655   France
Norvir
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom
   Clinical Alliance for Research & Education - Infectious Diseases, LLC.
      2006   Phase 4   NCT00426296   United States
Nucleomaxx
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00119379   United States
Nucleoside analogue sparing haart regimen
   Danish HIV Research Group
      2003   Phase 4   NCT00135460   Denmark
Obeticholic acid
   Abhimanyu Garg
      2016   Phase 2   NCT02430077   United States
Observation
   University of Texas Southwestern Medical Center
      2009   -   NCT01023620   United States
Olumiant
   Eli Lilly and Company
      -   Phase 2;Phase 3   EUCTR2025-000001-16-Outside-EU/EEA   Japan
Pegvisomant
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2023   Phase 2   NCT05470504   United States
Perform blood cells and fibroblasts biochemical and immuno-labeled investigations
   University Hospital, Bordeaux
      2014   -   NCT02056912   France
Pioglitazone
   French National Agency for Research on AIDS and Viral Hepatitis
      2003   Phase 3   NCT00148850   France
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2005   -   NCT00656851   United States
      2005   -   NCT00639457   United States
   Tufts Medical Center
      2011   Phase 4   NCT01612858   United States
   University of Texas Southwestern Medical Center
      2009   -   NCT01023620   United States
Pioglitazone or metformin
   Beth Israel Deaconess Medical Center
      2006   Phase 2   NCT00362440   United States
Pneumococcal polysaccharide vaccine 23 valent
   Medical University of South Carolina
      2015   Early Phase 1   NCT03039491   United States
POLY-L-lactic acid
   Kirby Institute
      2005   Phase 4   NCT00126308   Australia
Pravastatin
   Kirby Institute
      2001   Phase 4   NCT00227500   Australia
Pravastatin sodium
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00017758   United States
      2000   Phase 3   NCT00006412   Puerto Rico;United States
Prevenar13
   Maastricht University
      2016   Phase 4   EUCTR2015-004846-25-BE   Belgium
Protease inhibitor
   Bristol-Myers Squibb
      2005   Phase 4   NCT00135356   Canada;France;Germany;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   French National Agency for Research on AIDS and Viral Hepatitis
      2003   Phase 4   NCT00122668   France
Protease inhibitors
   French National Agency for Research on AIDS and Viral Hepatitis
      2001   Phase 4   NCT00122655   France
R-methuleptin
   Beth Israel Deaconess Medical Center
      2001   Phase 2   NCT00140244   United States
Raltegravir
   Southern California Institute for Research and Education
      2010   -   NCT01164605   United States
   University of California, Los Angeles
      2008   Phase 2   NCT00656175   Canada;United States
Recombinant human growth hormone
   Massachusetts General Hospital
      2004   -   NCT00100698   United States
Recombinant human growth hormone + rosiglitazone
   Weill Medical College of Cornell University
      2005   Phase 1/Phase 2   NCT00130286   United States
REGN4461
   Regeneron Pharmaceuticals
      2022   Phase 2   NCT05088460   France;Spain;Turkey;United Kingdom;United States
      2021   -   NCT04710056   -
   Regeneron Pharmaceuticals, Inc.
      2022   Phase 2   EUCTR2021-000138-33-FR   France;Spain;Turkey;United States
      2021   Phase 2   EUCTR2021-000138-33-ES   France;Spain;Turkey;United States
Reyataz
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom
   Clinical Alliance for Research & Education - Infectious Diseases, LLC.
      2006   Phase 4   NCT00426296   United States
Reyataz 150MG 60 CPS BL
   BRISTOL-M.SQUIBB
      2005   -   EUCTR2004-002740-10-IT   Germany;Italy;Spain;United Kingdom
Riboflavin
   Queen's University
      2002   Phase 4   NCT00202228   Canada
Ritonavir
   Bristol-Myers Squibb
      2005   Phase 4   NCT00135356   Canada;France;Germany;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom
   Clinical Alliance for Research & Education - Infectious Diseases, LLC.
      2006   Phase 4   NCT00426296   United States
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
Rosiglitazone maleate
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   -   NCT00015691   United States
RTV
   Bristol-Myers Squibb
      2005   Phase 4   NCT00135356   Canada;France;Germany;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States
   Bristol-Myers Squibb International Corporation
      2005   Phase 4   EUCTR2004-002740-10-GB   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-ES   Germany;Italy;Spain;United Kingdom
      2005   -   EUCTR2004-002740-10-DE   Germany;Italy;Spain;United Kingdom
Saquinavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
Setmelanotide
   Rhythm Pharmaceuticals, Inc.
      2017   -   NCT03262610   United States
Simvastatin
   National Institute of Allergy and Infectious Diseases (NIAID)
      2001   Phase 1   NCT00017758   United States
Somatropin
   EMD Serono
      2004   Phase 3   NCT00082628   Canada;United States
ST200
   SIGMA-TAU
      2006   -   EUCTR2005-004665-42-IT   Italy
Standard continuous antiretroviral therapy
   Hospital Clinic of Barcelona
      2002   Phase 4   NCT00646984   Spain
Stavudine
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      2000   Phase 4   NCT00006190   United States
Sustiva
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom
TAT4 GEL concentration A
   Topokine Therapeutics, Inc.
      2014   Phase 1   NCT02647853   United States
TAT4 GEL concentration B
   Topokine Therapeutics, Inc.
      2014   Phase 1   NCT02647853   United States
Tenofovir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
Tenofovir DF
   Gilead Sciences
      2003   Phase 2   NCT00647946   United Kingdom
Tenofovir disoproxil fumarate
   National Institute of Allergy and Infectious Diseases (NIAID)
      2005   Phase 2   NCT00119379   United States
   Thomas Benfield
      2021   Phase 4   NCT04903847   Denmark
Tesamorelin
   Columbia University
      2018   Phase 4   NCT03226821   United States
   Johns Hopkins University
      2012   -   NCT01788462   United States
   Massachusetts General Hospital
      2010   -   NCT01263717   United States
   Theratechnologies
      2007   Phase 3   NCT00608023   Belgium;Canada;France;Spain;United Kingdom;United States
   Theratechnologies Inc.
      2007   Phase 3   EUCTR2007-003233-16-GB   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-FR   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-ES   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-BE   Belgium;France;Spain;United Kingdom
Testosterone injection
   Queen's University
      1999   -   NCT00202241   Canada
TH9507
   Theratechnologies
      2005   Phase 3   NCT00123253   Canada;United States
   Theratechnologies Inc.
      2007   Phase 3   EUCTR2007-003233-16-GB   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-FR   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-ES   Belgium;France;Spain;United Kingdom
      2007   -   EUCTR2007-003233-16-BE   Belgium;France;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-005444-88-GB   Belgium;France;Germany;Spain;United Kingdom
      2007   Phase 3   EUCTR2006-005444-88-FR   Belgium;France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005444-88-ES   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005444-88-DE   France;Germany;Spain;United Kingdom
      2007   -   EUCTR2006-005444-88-BE   Belgium;France;Germany;Spain;United Kingdom
Thiamine
   Queen's University
      2002   Phase 4   NCT00202228   Canada
Tipranavir
   Kirby Institute
      2003   Phase 4   NCT00192660   Australia
Total dietary replacement
   Cambridge University Hospitals NHS Foundation Trust
      2020   -   NCT03900286   United Kingdom
Truvada
   University Hospital Birmingham
      2005   Phase 4   EUCTR2005-004021-26-GB   United Kingdom
Venus versa
   Venus Concept
      2015   -   NCT02492997   United States
Viral load driven treatment interruption
   Hospital Clinic of Barcelona
      2002   Phase 4   NCT00646984   Spain
Volanesorsen
   Ionis Pharmaceuticals, Inc.
      2015   Phase 2/Phase 3   NCT02527343   Belgium;Brazil;Canada;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
Volanesorsen sodium, APOC-III antisense oligonucleotide
   Akcea Therapeutics
      2016   Phase 2;Phase 3   EUCTR2015-000493-35-PT   Belgium;Brazil;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Akcea Therapeutics, Inc.
      2016   Phase 3   EUCTR2015-000493-35-DE   Belgium;Brazil;Canada;France;Germany;Greece;Israel;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   IONIS PHARMACEUTICALS, INC.
      2015   Phase 2;Phase 3   EUCTR2015-000493-35-IT   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Ionis Pharmaceuticals, Inc.
      2016   Phase 3   EUCTR2015-000493-35-GR   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2015   Phase 3   EUCTR2015-000493-35-BE   Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
   Isis Pharmaceuticals, Inc.
      2015   Phase 3   EUCTR2015-000493-35-NL   Australia;Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
      2015   Phase 2;Phase 3   EUCTR2015-000493-35-ES   Australia;Belgium;Brazil;Canada;France;Germany;Greece;Italy;Netherlands;Poland;Portugal;Russian Federation;Spain;Turkey;United Kingdom;United States
Zidovudine
   Kirby Institute
      2004   Phase 4   NCT00192621   Australia
      2003   Phase 4   NCT00192660   Australia